Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome
Top Cited Papers
- 15 May 2003
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (10) , 1912-1921
- https://doi.org/10.1200/jco.2003.05.073
Abstract
Purpose: Fibroblast growth factor receptor 3 (FGFR3) mutations were recently found at a high frequency in well-differentiated urothelial cell carcinoma (UCC). We investigated the relationship between FGFR3 status and three molecular markers (MIB-1, P53, and P27kip1) associated with worse prognosis and determined the reproducibility of pathologic grade and molecular variables.Keywords
This publication has 38 references indexed in Scilit:
- Methods for Genotyping Single Nucleotide PolymorphismsAnnual Review of Genomics and Human Genetics, 2001
- Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) TumorsThe American Journal of Pathology, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Distinct Missense Mutations of the FGFR3 Lys650 Codon Modulate Receptor Kinase Activation and the Severity of the Skeletal Dysplasia PhenotypeAmerican Journal of Human Genetics, 2000
- MIB-1 as a proliferative marker in transitional cell carcinoma of the bladderCancer, 2000
- p53 Immunohistochemistry as a Prognostic Marker in Bladder CancerEuropean Urology, 2000
- Loss of p27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancersEuropean Journal Of Cancer, 1999
- The genetics of transitional cell carcinoma: progress and potential clinical applicationBJU International, 1999
- The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic indexBritish Journal of Urology, 1998
- Factors affecting recurrence and progression in superficial bladder tumoursEuropean Journal Of Cancer, 1995